Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside [Yahoo! Finance]
Immatics N.V. - Ordinary Shares (IMTX)
Company Research
Source: Yahoo! Finance
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Immatics (NasdaqCM:IMTX) reported strong enrollment in its Phase 3 SUPRAME trial for anzu-cel (IMA203), its lead cancer immunotherapy candidate. The company has set timelines for the final analysis of the trial and is targeting a future product launch following completion. This update outlines the next key clinical and regulatory steps for Immatics' late stage oncology pipeline. Immatics focuses on T cell based cancer therapies, with anzu-cel at the center of its late stage efforts. For you as an investor, progress in a Phase 3 program can be a key reference point for how a biotech's clinical pipeline is maturing. The SUPRAME trial update adds detail on how Immatics is working to move from research toward a potential commercial product. Clear timelines for final analysis and a targeted launch give you a more concrete view of what the next milestones might
Show less
Read more
Impact Snapshot
Event Time:
IMTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMTX alerts
High impacting Immatics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
IMTX
News
- Immatics (IMTX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate [Yahoo! Finance]Yahoo! Finance
- Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot [Seeking Alpha]Seeking Alpha
- Immatics (IMTX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold"MarketBeat
- Immatics Announces Full Year 2025 Financial Results and Business Update [Yahoo! Finance]Yahoo! Finance
IMTX
Earnings
- 11/17/25 - Beat
IMTX
Sec Filings
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- IMTX's page on the SEC website